

**DRUG
REIMBURSEMENT
POLICY FOR
NEUROLOGICAL AND
PSYCHIATRIC
DISORDERS**

PLAN

I. INTRODUCTION

II. HEALTH INSURANCE

III. HEALTH INSURANCE EXPENSES

IV. DRUG REIMBURSEMENT EXPENSES

PLAN

**V. REIMBURSEMENT FOR CNS AND
PSYCHIATRY**

VI. CONCLUSIONS

I. Introduction

II. Health Insurance Financing

SOCIAL CONTRIBUTIONS
employers and employees

TAXES

National Office for Social Security
(RSZ - ONSS)


National institute for Sickness and
Invalidity Insurance (RIZIV -
INAMI)

Health Insurance Fund

COST OF MEDICAL ACT OR GOOD

CO or OUT-OF-POCKET PAYMENT by patient :
reimbursement system (ambulatory)
or third-party payer system (hospital)


III. Health Insurance Expenses



IV. DRUG REIMBURSEMENT EXPENSES

- 1. Key features**
- 2. Procedures**
- 3. Evaluation and decision**
- 4. Differential reimbursement (Out-patient)**
- 5. Reimbursement criteria**
- 6. Reimbursement in hospitals**

**HEALTH INSURANCE
REIMBURSEMENT 2004
TOTAL : 16.771 millions €**



1. Key Features

- ❖ **Positive list – nomenclature**
- ❖ **Unconditional reimbursement versus conditional reimbursement**
(chapter I versus chapters II and IV)
- ❖ **Reimbursement ambulatory versus hospital use**

1. Key Features

- ❖ **Differential reimbursement**

(self-employed persons versus salaried persons
(active versus WORD group)
category A B C Cs Cx D)
- ❖ **Reference Reimbursement System**
- ❖ **Revision**

1. Key Features

❖ **European Directive 89/105 – Transparency Directive**

deadlines

objective criteria

+ Evidence Based Medicine/Decision


+ Pharmacoeconomics

1. Key Features

❖ Principles adopted by the Government in October 2000

Legal basis established in Law of 14/07/1994
Execution by Royal Decree 21/12/2001

2. Procedures



3. Evaluation and Decision

1. THERAPEUTIC VALUE - ADDED VALUE

= EFFICACY + SAFETY + EFFECTIVENESS + APPLICABILITY + CONVENIENCE

as determined by

MORBIDITY - MORTALITY - QUALITY OF LIFE

class 1 added value

class 2 comparable value

class 3 generics copies

2. PRICE and LEVEL OF REIMBURSEMENT

3. IMPORTANCE IN CLINICAL PRACTICE (social and/or therapeutic needs)

4. BUDGETARY IMPACT

5. Ratio COST / THERAPEUTIC VALUE

4. Differential Reimbursement (out-patient)

Category	Health Insurance	Part
A	100%	0%
B	75%	25%
C	50%	50%
Cs	40%	60%
CX	20%	80%
D	0%	100%

*

5. Reimbursement Criteria

I. NO

II. Proof in the Medical Record based on guidelines to be controlled after the reimbursement

IV. Proof before the reimbursement to the physician advisor of the Health Insurance

6. Reimbursement in Hospitals

- ❖ **”Forfait” per pathology depending on
APR – DRG / (75%)**
- ❖ **25% per tablet or injection**
- ❖ **270 drugs out of the “forfait”**

V. REIMBURSEMENT FOR CNS AND PSYCHIATRY

1. Top 5 on 14 groups
2. Top 4 by DDD
3. Miscellaneous
4. Top 5 in psychiatry
5. Top 4 in neurology

V. REIMBURSEMENT FOR CNS AND PSYCHIATRY

6. Top 3 by neurologists and psychiatrists

7. Reimbursement conditions for active CNS drugs
in Belgium

1. Top 5 on 14 groups

Nettocost

1° **Cardiovasculars**

2° **CNS (16.4%) (450 Mio €)**

3° **GE – Metabolics**

4° **Cytostatics – Immunology**

5° **Antibiotics** ↘

63% of the total

2. Top 4 by DDD

1° Cardiovasculars

2° GE – Metabolics

3° CNS (9.9%)

4° Respiratory

3. Miscellaneous

- ❖ 1998 – 2004 : **↑ 6.7% (price)** **↑ 5.6% (volume)**
- ❖ CNS : n° 3 in % growth after

{	hematology
	immunology
- ❖ CNS n° 1 in expenses growth
- ❖ Co-payment in CNS : $\pm 20\%$
- ❖ GP = specialists

4. Top 5 in Psychiatry

(3) SSRI's	3.7% DDD	↗↗
(8) OTHER ANTIDEPRESSANTS	1.4% DDD	↗↗
(14) OPIOIDS	1% DDD	↗
(19) DIAZEPINES, OXAZEPINES, THIAZEPINES	0.2% DDD	↗
(30) ANTIPSYCHOTICS	0.3% DDD	↗

5. Top 4 in Neurology

(35) ANTIPILEPTICS

0.2% DDD ↗

(45) CHOLINESTERASE INHIBIT.

0.2% DDD ↗

(47) VALPROID ACIDS

0.3% DDD -

(67) DOPAMIN-AGONISTS

0.1% DDD -

6. Top 4 by neurologists and psychiatrists

- 1° Interferons
- 2° SSRI'S
- 3° Diazepines
- 4° Other antidepressants

7. Reimbursement Conditions for active CNS Drugs in Belgium

Hypnotics

D

Antipsychotics

Phenotiazines

B

Thioxanthenes

TM =

Butyrophenones

B

Diphenylpiperidines

TM =

Benzamides

B

TM =

GEN ++

7. Reimbursement Conditions for active CNS Drugs in Belgium

Antidepressants

Tricyclics

B

GEN ++

Inhibitors Monoamine Oxidases

B

TM =

Lithium

B

TM =

7. Reimbursement Conditions for active CNS Drugs in Belgium

CS stimulation

B

TM =

Antiparkinsonians

B / B IV

TM =

Antiepileptics

A / A IV

TM 

7. Reimbursement Conditions for active CNS Drugs in Belgium

Antimigraine

Imitrex injection

B IV

TM =

Sandomigran

Cx

Nocertone

TM =

VI. CONCLUSIONS